GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » PURE Bioscience Inc (OTCPK:PURE) » Definitions » Cash Conversion Cycle

PURE Bioscience (PURE Bioscience) Cash Conversion Cycle : -197.88 (As of Jan. 2024)


View and export this data going back to 1996. Start your Free Trial

What is PURE Bioscience Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

PURE Bioscience's Days Sales Outstanding for the three months ended in Jan. 2024 was 72.5.
PURE Bioscience's Days Inventory for the three months ended in Jan. 2024 was 54.51.
PURE Bioscience's Days Payable for the three months ended in Jan. 2024 was 324.89.
Therefore, PURE Bioscience's Cash Conversion Cycle (CCC) for the three months ended in Jan. 2024 was -197.88.


PURE Bioscience Cash Conversion Cycle Historical Data

The historical data trend for PURE Bioscience's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PURE Bioscience Cash Conversion Cycle Chart

PURE Bioscience Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -135.34 -35.35 -36.55 -65.91 -82.28

PURE Bioscience Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.10 -54.41 -64.33 -103.77 -197.88

Competitive Comparison of PURE Bioscience's Cash Conversion Cycle

For the Household & Personal Products subindustry, PURE Bioscience's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PURE Bioscience's Cash Conversion Cycle Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, PURE Bioscience's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where PURE Bioscience's Cash Conversion Cycle falls into.



PURE Bioscience Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

PURE Bioscience's Cash Conversion Cycle for the fiscal year that ended in Jul. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=47.25+53.78-183.31
=-82.28

PURE Bioscience's Cash Conversion Cycle for the quarter that ended in Jan. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=72.5+54.51-324.89
=-197.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PURE Bioscience  (OTCPK:PURE) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


PURE Bioscience Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of PURE Bioscience's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


PURE Bioscience (PURE Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
771 Jamacha Road, No. 512, El Cajon, CA, USA, 92019
PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, products preserved with SDC and SDC as a raw material ingredient for manufacturing use.
Executives
Robert F Bartlett director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Bernard Blotner director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Tom Y Lee director 1807 SAN GABRIEL BLVD., SAN GABRIEL CA 91776
David Rendall director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Kristin Taylor director 13500 EVENING CREEK DRIVE N, SUITE 550, SAN DIEGO CA 92128
Dale Okuno director 35 N. ARROYO PARKWAY, SUITE 1, PASADENA CA 91103
Ivan Chen director 1725 GILLESPIE WAY, EL CAJON CA 92020
Thomas Richard Myers officer: Chief Operating Officer 1725 GILLESPIE WAY, EL CAJON CA 92130
Henry R. Lambert director, officer: Chief Executive Officer 1725 GILLESPIE WAY, EL CAJON CA 92020
Elisabeth Hagen director 1725 GILLESPIE WAY, EL CAJON CA 92020
Janet Risi Field director 9200 SOUTH DADELAND BOULEVARD, SUITE 800, MIAMI FL 33156
Franchise Brands, Llc 10 percent owner 325 BIC DRIVE, MILFORD CT 06461
Mark Stuart Elliott officer: Vice President, Finance 1725 GILLESPIE WAY, EL CAJON CA 92020
William Otis director 1725 GILLESPIE WAY, EL CAJON CA 92020
David M Theno director 1725 GILLESPIE WAY, EL CAJON CA 92020